Rinvoq ER 15 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DR26F12XV
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,471
Award facts
- Contract value 100% obligated
- $9,470.81 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $9,470.81 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 3, 2025, with an ultimate completion date of November 4, 2025. This non-compete award was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement valued through December 2026 that serves as the primary pharmaceutical supply vehicle for global military healthcare operations. The delivery location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania.
As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp fulfills delivery orders for a comprehensive range of pharmaceutical products, medical supplies, and specialty medications across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. RINVOQ (upadacitinib) is a Janus kinase inhibitor used for inflammatory conditions including rheumatoid arthritis and atopic dermatitis. This delivery order represents one of numerous competitively awarded transactions under AmerisourceBergen's master pharmaceutical supply agreement, demonstrating the company's role as a key vendor in the Department of Defense's medical supply chain.
Quick answers
Who was awarded contract SPE2DR26F12XV?
SPE2DR26F12XV was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 3, 2025.
How much is contract SPE2DR26F12XV worth?
The government has obligated $9,471 on SPE2DR26F12XV.
Is contract SPE2DR26F12XV an order under another contract?
Yes. SPE2DR26F12XV is a delivery order under SPE2DR25D1110, an indefinite delivery contract.
Was contract SPE2DR26F12XV competed?
The extent of competition for SPE2DR26F12XV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award